<DOC>
	<DOCNO>NCT01739309</DOCNO>
	<brief_summary>The purpose study estimate disease control rate LY2835219 relapse refractory mantle cell lymphoma .</brief_summary>
	<brief_title>Study LY2835219 Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<criteria>Have diagnosis relapse refractory Mantle Cell Lymphoma ( MCL ) accord World Health Organization ( WHO ) classification relapse , refractory , available standard treatment . However , participant intolerant , unable receive standard treatment require MCL relapse , refractory , specific standard treatment . Pathology must review confirmed investigational site participant enter prior enrollment Have disease assessable accord Response Criteria Non Hodgkin 's Lymphomas Have give write informed consent prior studyspecific procedure Have adequate organ function include : Hematologic : Absolute neutrophil count ( ANC ) ≥1.5 x 10^9/Liter ( L ) , platelets ≥75 x 10^9/L , hemoglobin ≥8 gram per deciliter ( g/dL ) Hepatic : Bilirubin ≤1.5 time upper limit normal ( ULN ) alanine aminotransferase ( ALT ) ≤3.0 time ULN Renal : Estimated creatinine clearance ≥50 milliliter per minute ( ml/min ) Have Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 Have discontinue previous therapy cancer ( include chemotherapy , radiotherapy , immunotherapy , investigational therapy ) least 21 day myelosuppressive agent 14 day nonmyelosuppressive agent prior receive study drug , recover acute effect therapy ( treatmentrelated toxicity resolve baseline ) except residual alopecia Are willing make available duration study follow study procedure Are amenable compliance protocol schedule test Males female reproductive potential must agree use medically approve contraceptive precaution trial 3 month follow last dose study drug Females childbearing potential must negative serum pregnancy test within 14 day first dose study drug Have life expectancy ≥12 week Are able swallow capsule Are currently enrol , discontinue within 14 21 day initial dose study drug nonmyelosuppressive myelosuppressive agent , respectively , clinical trial involve investigational product nonapproved use drug device study drug use study , concurrently enrol type medical research judge scientifically medically compatible study Have serious preexist medical condition , judgment investigator , would preclude participation study ( example , pneumonia , inflammatory bowel disease , history major surgical resection involve stomach small bowel ) Have symptomatic metastasis central nervous system ( CNS ) . Participants may CNS metastasis radiographically clinically stable least 14 day prior receive study drug , regardless whether receive corticosteroid Have receive autologous allogeneic stemcell transplant within 75 day initial dose study drug . In addition , recipient allogenic stemcell transplant must discontinue immunosuppressive therapy least 14 day study drug administration Grade 1 acute graft versushost disease Day 1 Cycle 1 Females pregnant lactating Have active bacterial , fungal , and/or know viral infection ( example , human immunodeficiency virus [ HIV ] antibody , hepatitis B surface antigen [ HBSAg ] , hepatitis C antibody ) . Screening require enrollment Have baseline electrocardiogram ( ECG ) follow finding : ventricular tachycardia , ventricular fibrillation , abnormal QTcB ( define ≥450 milliseconds male ≥470 milliseconds female ) , evidence acute myocardial ischemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non- Hodgkins Lymphoma</keyword>
</DOC>